For research use only. Not for therapeutic Use.
Taltobulin (Cat No.:I002738) is a synthetic tubulin inhibitor with potent antitumor activity. It binds to the colchicine-binding site on tubulin, disrupting microtubule dynamics and inhibiting cell division. Taltobulin exhibits selective cytotoxicity towards cancer cells, inducing mitotic arrest and subsequent apoptosis. It has shown efficacy against a range of solid tumors, including breast, lung, and ovarian cancers. Taltobulin’s unique mechanism of action and promising preclinical results make it a potential candidate for further development as an anticancer therapy. Clinical trials are underway to evaluate its safety and efficacy in cancer patients.
| Catalog Number | I002738 |
| CAS Number | 228266-40-8 |
| Synonyms | HTI-286; |
| Molecular Formula | C27H43N3O4 |
| Purity | ≥95% |
| Target | tubulin |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>Taltobulin is a <span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Tubulin polymerisation inhibitor. The </span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Phase-I clinical trials in Cancer in USA (unspecified route) is ongoing.</span></span></span></span> |
| IUPAC Name | (E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid |
| InChI | InChI=1S/C27H43N3O4/c1-17(2)20(16-18(3)25(33)34)30(10)24(32)22(26(4,5)6)29-23(31)21(28-9)27(7,8)19-14-12-11-13-15-19/h11-17,20-22,28H,1-10H3,(H,29,31)(H,33,34)/b18-16+/t20-,21-,22-/m1/s1 |
| InChIKey | CNTMOLDWXSVYKD-PSRNMDMQSA-N |
| SMILES | CC(C)[C@@H](/C=C(\C)/C(=O)O)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C(C)(C)C1=CC=CC=C1)NC |
| Reference | <br /> |
